NCT04666610
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Registry fields
- Overall status
- COMPLETED
- Conditions
- Childhood Absence Epilepsy, Juvenile Absence Epilepsy
- Study type
- INTERVENTIONAL
- Phase
- PHASE3
- Primary purpose
- TREATMENT
- Intervention type
- DRUG, OTHER
- Interventions
- Brivaracetam, Placebo
- Lead sponsor
- UCB Biopharma SRL (INDUSTRY)
Cached at: 2026-07-24 09:04:06
Brief summary
The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue